Aurinia Pharmaceuticals (AUPH) to Release Quarterly Earnings on Thursday

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) is expected to post its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $0.21 per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 9:30 AM ET.

Aurinia Pharmaceuticals Price Performance

AUPH stock opened at $14.31 on Thursday. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.76 and a quick ratio of 5.17. The company’s 50-day moving average is $15.17 and its 200-day moving average is $13.78. The stock has a market capitalization of $1.89 billion, a PE ratio of 25.55 and a beta of 1.50. Aurinia Pharmaceuticals has a 1 year low of $6.55 and a 1 year high of $16.54.

Wall Street Analyst Weigh In

Several research analysts have issued reports on AUPH shares. Bloom Burton lowered Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a report on Wednesday, November 5th. Leerink Partners cut Aurinia Pharmaceuticals from an “outperform” rating to a “market perform” rating and increased their target price for the stock from $15.00 to $16.00 in a report on Wednesday, December 3rd. Weiss Ratings reissued a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, January 21st. Jefferies Financial Group upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price objective for the stock from $10.00 to $21.00 in a report on Friday, November 7th. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $15.00 price objective (up from $9.00) on shares of Aurinia Pharmaceuticals in a research note on Wednesday, November 5th. Two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $17.25.

Institutional Trading of Aurinia Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. nVerses Capital LLC purchased a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter valued at about $406,000. Uniplan Investment Counsel Inc. grew its position in Aurinia Pharmaceuticals by 31.3% in the 4th quarter. Uniplan Investment Counsel Inc. now owns 120,202 shares of the biotechnology company’s stock worth $1,917,000 after purchasing an additional 28,645 shares in the last quarter. Voloridge Investment Management LLC increased its stake in Aurinia Pharmaceuticals by 44.3% in the 4th quarter. Voloridge Investment Management LLC now owns 739,444 shares of the biotechnology company’s stock valued at $11,794,000 after buying an additional 226,875 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Aurinia Pharmaceuticals by 4.7% during the 4th quarter. Wellington Management Group LLP now owns 53,721 shares of the biotechnology company’s stock worth $857,000 after buying an additional 2,421 shares in the last quarter. Finally, Millennium Management LLC lifted its position in shares of Aurinia Pharmaceuticals by 634.1% during the 4th quarter. Millennium Management LLC now owns 738,306 shares of the biotechnology company’s stock worth $11,776,000 after buying an additional 637,733 shares in the last quarter. Institutional investors own 36.83% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.